TY - JOUR
T1 - Choosing treatment for stage I seminoma
T2 - Who should get what?
AU - Garmezy, Benjamin
AU - Pagliaro, Lance C.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2009/8
Y1 - 2009/8
N2 - We agree that physicians should choose active surveillance for their patients if they have the means to afford health insurance and are relatively stable within their careers. Prophylactic radiotherapy should be offered to patients who need a relaxed follow-up schedule for financial, emotional, or compliance reasons. For adjuvant carboplatin, longer follow-up data are needed to better define survival, long-term toxicities, frequency of second primary testicular cancers, quality of life, and cost to the health-care system.
AB - We agree that physicians should choose active surveillance for their patients if they have the means to afford health insurance and are relatively stable within their careers. Prophylactic radiotherapy should be offered to patients who need a relaxed follow-up schedule for financial, emotional, or compliance reasons. For adjuvant carboplatin, longer follow-up data are needed to better define survival, long-term toxicities, frequency of second primary testicular cancers, quality of life, and cost to the health-care system.
UR - http://www.scopus.com/inward/record.url?scp=70349291320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349291320&partnerID=8YFLogxK
M3 - Comment/debate
AN - SCOPUS:70349291320
SN - 0890-9091
VL - 23
JO - ONCOLOGY
JF - ONCOLOGY
IS - 9
ER -